MAPT and Alzheimer disease: The serum N-glycan NA2F level was substantially decreased in patients with AD, but not in controls, and significantly correlated with the CSF Aβ(1-42) and Tau phosphorylated at threonine 181 (P-tau(181P)) levels [20].